Advances in the study of pharmacological treatments for meningiomas
10.3781/j.issn.1000-7431.2024.2401-0013
- VernacularTitle:脑膜瘤的药物治疗研究进展
- Author:
Xiaojie LI
1
;
Sipeng ZHU
1
;
Zhen WU
1
Author Information
1. 首都医科大学附属北京天坛医院神经外科,北京 100071
- Publication Type:Journal Article
- Keywords:
Meningiomas;
Cytotoxic drugs;
Targeted Therapy;
Immunotherapy
- From:
Tumor
2024;44(9):905-915
- CountryChina
- Language:Chinese
-
Abstract:
Meningioma is the most common primary intracranial tumor,of which about 20％are high-grade tumors,with a high recurrence rate after surgery and poorly controlled by radiotherapy,requiring adjuvant pharmacological treatment.Cytotoxic drugs were applied at the beginning,but the efficacy was poor with significant side effects.Subsequently,targeted drugs such as tyrosine kinase inhibitors and somatostatin analogs were used for treatment,and the prognosis of meningioma patients was improved.With the development of new technologies such as high-throughput sequencing,more potential targets have been revealed.There exists a suppressive immune microenvironment within meningiomas,and modulation of lymphocytes and myeloid cells can rescue the intrinsic immune function of the tumor,and relevant clinical trials are in progress.This article reviewed the research progress of pharmacological treatment of meningiomas,and the current situation and prospects of drug therapy ware discussed and prospected.
